Major players in the nebulizer device market are Agilent Technologies, Becton Dickinson and Company, Koninklijke Philips NV, Omron Corporation, Covidien plc, GE Healthcare Ltd., Allied Healthcare Products, Inc, Briggs Healthcare, PARI Pharma and GF Health Products, Inc .
New York, April 23, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the release of the “Nebulizers Global Market Report 2021: COVID 19 Implications And Growth to 2030” – https://www.reportlinker.com/p06065178/? utm_source = GNW
The global nebulizer market is expected to decline from $ 1.67 billion in 2020 to $ 1.04 billion in 2021, with a compound annual growth rate (CAGR) of -37.7%. The change in the growth trend is mainly due to companies stabilizing their production after meeting the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is projected to reach $ 1.55 billion in 2025 with a CAGR. 10.5%.
The nebulizer market consists of the sale of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis and COPD. Sales consist of revenues generated by factories which are mainly engaged in the production of pneumatic driven and ventilated nebulizers, portable and autonomous ultrasonic nebulizers and static and vibrating mesh nebulizers.
The current Covid-19 pandemic has resulted in an increase in demand for nebulizers.There has been an increase in the use of albuterol inhalers in hospitals for Covid-19 and Covid-19 suspected patients to help with respiratory problems.
This is mainly due to the fact that respiratory viruses are the most common trigger for asthma exacerbations.
Nebulizer therapy requires a device that repeatedly and rapidly delivers a sufficient amount of drug with minimal waste, at the site of action. However, during nebulization, aerosols with smaller particles are inhaled or delivered to the site of action as the larger particles return to the reservoir feed tube.
In addition, some of the aerosols of the drug are deposited on the walls of the deflector.
This results in drug waste, which on exhalation is therefore challenging the growth of the nebulizer market.
However, the development of new technically advanced nebulizers is expected to reduce drug waste and improve delivery effectiveness.
Technologically advanced nebulizers, including enhanced mesh, breath-activated and vibrating nebulizers, reduce the amount of drug lost on exhalation, increasing drug delivery efficiency and shaping the nebulizer device market. Healthcare technology platform development company, revealed the introduction of a drug-centric commercial development program for its RespiRx drug delivery system.
Respirx is a compact hand-held vibrating mesh nebulizer built for local and systemic treatment and can operate in any position placed by the patient. Newer and more advanced nebulizers increase the output rate which in turn will decrease the delivery time.
The increase in the geriatric population worldwide is expected to increase the use of respiratory assistance devices, including nebulizers, over the forecast period. Total 2 billion, compared to 900 million in 2015.
In 2019, 143 million people were 80 or older. According to the United Nations, in 2020, the world population of people aged 65 and over was estimated at 727 million and this number is projected to nearly double to over 1.5 billion in 2050. Older people are more susceptible to respiratory diseases such as chronic obstructive pulmonary disease (COPD), sleep apnea and the recent COVID-19 pandemic for many factors, including the gradual decline in immune function. Therefore, the increase in the geriatric population is expected to stimulate the growth of the nebulizer market.
Read the full report: https://www.reportlinker.com/p06065178/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need, instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001